Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study

Conclusions
Efficacy was sustained over 112 weeks in individuals with difficult-to-treat EM for whom 2–4 prior migraine preventives had failed. Erenumab treatment was safe and well tolerated, in-line with previous studies.

Trial registration number
NCT03096834

Source: Journal of Neurology, Neurosurgery and Psychiatry - February 15, 2022 Category: Neurosurgery Authors: Ferrari, M. D., Reuter, U., Goadsby, P. J., Paiva da Silva Lima, G., Mondal, S., Wen, S., Tenenbaum, N., Pandhi, S., Lanteri-Minet, M., Stites, T. Tags: Open access Migraine Source Type: research